In vitro study of lovastatin interactions with amiodarone and with carbon tetrachloride in isolated rat hepatocytes

World Journal of Gastroenterology

Volumn 13, Issue 15, 2007, Pages 2198-2204

  Krasteva, A Z ^a   Mitcheva, M K ^a   Kondeva Burdina, M S ^a   Descatoire, V Adria ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b BICHAT HOSPITAL   (France)

Author keywords

Amiodarone; Carbon tetrachloride; Hepatocytes; Interaction; Lovastatin

Indexed keywords

AMIODARONE; CARBON TETRACHLORIDE; COLLAGENASE; CYTOCHROME P450 2B1; GLUTATHIONE; LACTATE DEHYDROGENASE; MEVINOLIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL PROTECTION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; LIPID PEROXIDATION; LIVER CELL; LIVER MICROSOME; LIVER PERFUSION; MALE; MONOTHERAPY; NONHUMAN; RAT;

EID: 34249814942     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i15.2198     Document Type: Article

References (35)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430
2. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000; 40: 637-644
3. Rousseau G, Veronneau M, Des Rosiers C, Varin F. Effects of lovastatin and pravastatin on ubiquinone and 4-hydroxynonenal tissue levels in the hypercholestrolemic hamster. Curr Ther Res 1999; 60: 87-104
4. Willis RA, Folkers K, Tucker JL, Ye CQ Xia LJ, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990; 87: 8928-8930
5. Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med 1991; 82: 233-235
6. Bruguera M, Joya P, Rodes J. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases. Gastroenterol Hepatol 1998; 21: 127-128
7. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994; 39: 2032-2033
8. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999; 94: 1388-1390
9. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004; 67: 2175-2186
10. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431
11. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305
12. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-268
13. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569-575
14. El-Swefy S, Schaefer EJ, Seman LJ, van Dongen D, Sevanian A, Smith DE, Ordovas JM, El-Sweidy M, Meydani M. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters. Atherosclerosis 2000; 149: 277-286
15. Mitcheva M, Kondeva M, Vitcheva V, Nedialkov P, Kitanov G. Effect of benzophenones from Hypericum annulatum on carbon tetrachloride-induced toxicity in freshly isolated rat hepatocytes. Redox Rep 2006; 11: 3-8
16. Berson A, Renault S, Letteron P, Robin MA, Fromenty B, Fau D, Le Bot MA, Riche C, Durand-Schneider AM, Feldmann G, Pessayre D. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996; 110: 1878-1890
17. Kocarek TA, Reddy AB. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos 1996; 24: 1197-1204
18. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-136
19. Robin MA, Maratrat M, Loeper J, Durand-Schneider AM, Tinel M, Ballet F, Beaune P, Feldmann G, Pessayre D. Cytochrome P4502B follows a vesicular route to the plasma membrane in cultured rat hepatocytes. Gastroenterology 1995; 108: 1110-1123
20. Bergmeyer HU, Gawehn K, Grassil M. Methods of enzymatic analysis 3th ed. In: Verlag Chemie, Weinheim, H.U. Bergmeyer (eds.). 1974; 1: 481-482
21. Fau D, Berson A, Eugene D, Fromenty B, Fisch C, Pessayre D. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 1992; 263: 69-77
22. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 2000; 21: 353-364
23. Kitamura S, Shimizu Y, Shiraga Y, Yoshida M, Sugihara K, Ohta S. Reductive metabolism of p,p'-DDT and o,p'-DDT by rat liver cytochrome P450. Drug Metab Dispos 2002; 30: 113-118
24. Kim HJ, Chun YJ, Park JD, Kim SI, Roh JK, Jeong TC. Protection of rat liver microsomes against carbon tetrachloride-induced lipid peroxidation by red ginseng saponin through cytochrome P450 inhibition. Planta Med 1997; 63: 415-418
25. Tirkey N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol 2005; 5: 2
26. Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE. Toxic liver damage caused by HMG-CoA reductase inhibitor. Med Klin (Munich) 2000; 95: 642-644
27. Huchzermeyer H, Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis. Dtsch Med Wochenschr 1995; 120: 252-256
28. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000; 49: 244-253
29. Raveh D, Arnon R, Israeli A, Eisenberg S. Lovastatin-induced hepatitis. Isr J Med Sci 1992; 28: 101-102
30. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989; 248: 498-505
31. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204
32. Lluis JM, Colell A, Garcia-Ruiz C, Coll O, Kaplowitz N, Fernandez-Checa JC. Acetaldehyde sensitizes HepG2 cells to tumor necrosis factor by imparing mitochondrila GSH transport through reticulum endoplasmic stress. Gastroenterology 2007; In press
33. Lluis JM, Colell A, Garcia-Ruiz C, Kaplowitz N, Fernandez-Checa JC. Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology 2003; 124: 708-724
34. Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, Rhee SJ, Choi MS. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. Life Sci 2001; 69: 2855-2866
35. Ha HR, Bigler L, Binder M, Kozlik P, Stieger B, Hesse M, Altorfer HR, Follath F. Metabolism of amiodarone (part I): identification of a new hydroxylated metabolite of amiodarone. Drug Metab Dispos 2001; 29: 152-158